REGULATORY

• Relief Claims OK’ed for 14 More Deaths Possibly Tied to COVID Jabs
  May 29, 2023

• Japan Approves Label Expansions for Ultomiris, Skyrizi, Vanflyta
  May 26, 2023

• Expert Panel Meeting Canceled Due to Lack of Coordination: MHLW Official
  May 26, 2023

• Expedite Introduction of High-Priority Vaccines into National Schedule: Trade Groups
  May 25, 2023

• Orphan Tag Granted to Opdivo, Leniolisib, and 6 More APIs
  May 24, 2023

• LDP Pharma Study Group Proposes Removing Cap for Social Security Costs
  May 23, 2023

• Ophthalmic Mitomycin, OD Tablets for Takecab and Tarlige to Get Listing on May 24
  May 23, 2023

• MHLW Cancels Expert Panel Meeting on May 23, Report Delayed
  May 23, 2023

• Ferring’s Oral Budesonide for UC Treatment Up for Advisor Review on June 2
  May 22, 2023

• PMDA Reviewing Safety Risks for Opdivo, Yervoy
  May 22, 2023

• Novo Mum over Pass on Wegovy Listing in May
  May 19, 2023

• Japan Eyes Pilot Program for OTC-Switching of Emergency Contraceptives, Public Commenters Overwhelmingly Positive
  May 18, 2023

• LDP Committee Calls for Setting Up Asian Hub of PMDA
  May 18, 2023

• Industry Associations Stress Special Cost Structure of SaMD in Chuikyo Hearing
  May 18, 2023

• Market Expansion Re-Pricing to Hit Tarlige, Entresto, Verzenio; Spillover to 2 Other Meds
  May 18, 2023

• Deregulation Panel Eyes Use of Medical Data “Without Patient Consent”
  May 17, 2023

• LDP Project Team to Finalize Pharma Policy Proposal for Honebuto by May-End, Submit It to Prime Minister
  May 17, 2023

• Create Command Tower to Integrate Innovation Support and Drug Pricing Policy: LDP Project Chief
  May 17, 2023

• Chuikyo OKs Listing of Omvoh, Entyvio SC, Besremi, and More; Biggest Sales Outlook for Lilly Drug
  May 17, 2023

• Novo’s Obesity Drug Wegovy Skips May Listing, Sobi’s Empaveli Too
  May 17, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 84
• 85
• 86
• 87
• 88
• 89
• 90
• 91
• 92
• …
• Next ›
• 最終 »